Drugs / ENOTICUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00871559 | Jun 2009 → Feb 2014 | high grade malignant neoplasm | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENOTICUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109385 ↗ |
| Known as | REGN421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00871559 ↗ |
| Known as | SAR153192 | “REGN421(SAR153192)” NCT00871559 ↗ |
| Action | Inhibit | “Delta-like protein 4 inhibitor” CHEMBL2109385 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109385 ↗ |
| Target | DLL4 | “Delta-like protein 4 inhibitor” CHEMBL2109385 ↗ |